Sonographic examination with microbubble contrast agents can reliably characterize focal liver lesions, confirm or exclude hepatocellular carcinomas, and remove the need for more invasive, costly imaging, according to studies presented Monday.
Sonographic examination with microbubble contrast agents can reliably characterize focal liver lesions, confirm or exclude hepatocellular carcinomas, and remove the need for more invasive, costly imaging, according to studies presented Monday.
Canadian researchers used contrast-enhanced ultrasound to evaluate 80 patients who presented during a nine-month period with 106 hepatic nodules that had a high likelihood of becoming malignant. The researchers characterized lesions during dynamic and portal vein phase scanning based on the lesions' enhancement patterns. They found that contrast sonography could characterize lesions early and obviate further scanning with CT or MR.
Contrast ultrasound confirmed 46 lesions as HCC, 31 as dysplastic/regenerative nodules, 16 as hemangiomas, eight as pseudomasses, and five as indeterminate nodules. Twenty-one out of 37 nodules detected at initial scanning were benign and were subjected to close surveillance with ultrasound only. None of these lesions evolved into HCC after the nine-month follow-up. Fifteen nodules were diagnosed as HCCs and one as a pseudomass.
Of 69 lesions with an indeterminate diagnosis at initial CT/MR scanning, contrast ultrasound identified 30 HCCs, 19 dysplastic/regenerative nodules, seven hemangiomas, and eight pseudomasses.
In a similar study, Italian researchers enrolled 191 consecutive patients with chronic diffuse liver disease due to chronic hepatitis B or C and cirrhosis. Using microbubble contrast sonography, the researchers accurately differentiated HCCs from other focal liver lesions.
As in the previous study, the investigators used the lesions' enhancement patterns at different phases to calculate positive predictive values. Two independent observers reviewed the studies. HCCs showed 40 diffuse homogeneous, 56 heterogeneous, 10 dotted, and five absent enhancement patterns at arterial phase. HCC also appeared as 71 hypoechoic lesions and 40 isoechoic lesions at late phase.
The investigators obtained the highest positive predictive value for HCCs by combining diffuse heterogeneous enhancement at arterial phase with hypoechoic appearance at late phase, with a PPV of 94% and overall accuracy in HCC characterization of 92%.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.